news
Anonymous FDA Petition Challenges Usona's Fast-Track Psilocybin Application
An unnamed client filed an FDA Citizen Petition on November 17 targeting Usona Institute's synthetic psilocybin application. The filing demands regulators hold the 25 mg depression treatment to the same strict trial standards that sank Lykos's MDMA bid earlier this year.
An unnamed client filed an FDA Citizen Petition on November 17 targeting Usona Institute's synthetic psilocybin application. The filing demands regulators hold the 25 mg depression treatment to the same strict trial standards that sank Lykos's MDMA bid earlier this year.
The architecture take
Someone in biotech just spent serious legal fees to slow down non-profit psilocybin, and I am not surprised in the slightest. Usona Institute is running phase 3 trials with a single 25 mg dose of synthetic psilocybin for major depression, aiming for approval without proprietary therapy attached. The anonymous petition asks the FDA for identical scrutiny on functional unblinding, precisely what cratered Lykos's MDMA application in August. I used to think the biggest hurdle for psychedelic medicine was federal scheduling, but I was naive. I watch these regulatory filings because they show where venture capital actually feels threatened. If Usona secures approval as an open-science non-profit, for-profit startups with patent portfolios lose their pricing power overnight. Serotonin 5-HT2A agonism creates a rapid window of neuroplasticity, yet the fight in Washington is about who charges four figures for the session. That part stays ugly.